DeFord John A
DeFord John A's purchase track record
DeFord John A has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/12/2024 | MRVI | $101K | -25.6% | -63.9% | -1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript. Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RBC Lowers Globus Medical Price Target to $85. RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.
Transaction History
| NDSN | ▲ Buy | Grant | 84 | $25K | 7/31/2026 | View on chart |
| MRVI | ▲ Buy | Grant | 46,293 | $0 | 5/26/2026 | View on chart |
| NDSN | ▲ Buy | Grant | 87 | $25K | 4/30/2026 | View on chart |
| NDSN | ▲ Buy | Grant | 91 | $25K | 1/30/2026 | View on chart |
| NDSN | ▲ Buy | Grant | 822 | $191K | 11/1/2025 | View on chart |
| MRVI | ▲ Buy | Grant | 89,139 | $193K | 6/16/2025 | View on chart |
| MRVI | ▲ Buy | Open Market | 17,500 | $101K | 11/12/2024 | View on chart |
| NDSN | ▲ Buy | Grant | 747 | $186K | 11/1/2024 | View on chart |
| MRVI | ▲ Buy | Grant | 20,645 | $223K | 5/23/2024 | View on chart |
| NDSN | ▲ Buy | Grant | 749 | $158K | 11/1/2023 | View on chart |
| NDSN | ▲ Buy | Grant | 105 | $22K | 10/31/2023 | View on chart |
| GMED | ▲ Buy | Grant | 15,578 | — | 9/1/2023 | View on chart |
| NDSN | ▲ Buy | Grant | 89 | $22K | 7/31/2023 | View on chart |
| MRVI | ▲ Buy | Grant | 31,901 | $0 | 7/20/2023 | View on chart |
| NDSN | ▲ Buy | Grant | 104 | $22K | 4/28/2023 | View on chart |
| NDSN | ▲ Buy | Grant | 92 | $22K | 1/31/2023 | View on chart |
| NDSN | ▲ Buy | Grant | 730 | $165K | 11/1/2022 | View on chart |
| NDSN | ▲ Buy | Grant | 100 | $23K | 10/31/2022 | View on chart |
| NDSN | ▲ Buy | Grant | 97 | $22K | 7/29/2022 | View on chart |
| NDSN | ▲ Buy | Grant | 104 | $22K | 4/29/2022 | View on chart |
| NDSN | ▲ Buy | Grant | 96 | $22K | 1/31/2022 | View on chart |
| NDSN | ▲ Buy | Grant | 608 | $145K | 11/1/2021 | View on chart |
| NDSN | ▲ Buy | Grant | 79 | $20K | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Nordson Packaging Recovery Cited Amid Valuation Concerns
Recent commentary highlights a genuine recovery in Nordson's packaging segment, though analysts note the stock price reflects this optimism. The company trades at a trailing P/E of 32.8, which some view as a premium relative to its current valuation. With the stock near its 52-week high, the market is closely watching whether operational improvements can justify the current price point.
Nordson Packaging Recovery Cited Amid Valuation Concerns. Recent commentary highlights a genuine recovery in Nordson's packaging segment, though analysts note the stock price reflects this optimism. The company trades at a trailing P/E of 32.8, which some view as a premium relative to its current valuation. With the stock near its 52-week high, the market is closely watching whether operational improvements can justify the current price point.